Abstract
We have identified kamebakaurin as an inhibitor of NF-κB and elucidated its molecular mechanism as a specific inhibitor in the DNA-binding activity of the p50 subunit of NF-κB. Here, we describe its anti-inflammatory activity in in vitro and in vivo models. Kamebakaurin dose-dependently inhibited not only the expression of inflammatory NF-κB target genes such as iNOS, COX-2, and TNF-α, but also the production of PGE2 and TNF-α in LPS-stimulated RAW264.7 cells. Moreover, in an air pouch model of inflammation, it suppressed the recruitment of neutrophils, production of TNF-α as well as PGE2 in the pouch exudates induced by carrageenan. In addition, kamebakaurin dose-dependently suppressed the inflammation in an adjuvant arthritis model. Oral administration of 20 mg/kg kamebakaurin resulted in the 75 % decrease of paw volume. Taken together, kamebakaurin, a specific inhibitor of DNA-binding activity of the p50 subunit, is a valuable candidate for the intervention in NF-κB-dependent pathological conditions such as inflammation.
Key words
Diterpene - kamebakaurin - NF-κB - p50 - anti-inflammation - air pouch - adjuvant arthritis
References
1
Baldwin A S.
The NF-κB and IκB proteins: new discoveries and insights.
Annu Rev Immunol.
1996;
14
649-81
2
Ghosh S, May M J, Kopp E B.
NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses.
Annu Rev Immunol.
1998;
16
225-60
3
Barkett M, Gilmore T D.
Control of apoptosis by Rel/NF-kappaB transcription factors.
Oncogene.
1999;
18
6910-24
4
Wang C Y, Mayo M W, Korneluk R G, Goeddel D V, Baldwin A S.
NF-κB anti-apoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.
Science.
1998;
281
1680-3
5
Baeuerle P A, Baltimore D A.
65-kD subunit of active NF-κB is required for inhibition of NF-κB by IκB.
Genes Dev.
1989;
3
1689-98
6
Ballard D W, Dixon E P, Peffer N J, Bogerd H, Doerre S, Stein B, Greene W C.
The 65-kDa subunit of human NF-κB functions as a potent transcriptional activator and a target for v-Rel-mediated repression.
Proc Natl Acad Sci USA.
1992;
89
1875-9
7
Schmitz M L, Baeuerle P.
The p65 subunit is responsible for the strong transcription activating potential of NF-κB.
EMBO J.
1991;
10
3805-17
8
Pahl H L.
Activators and target genes of Rel/NF-κB transcription factors.
Oncogene.
1999;
18
6853-66
9
Yamamoto Y, Gaynor R B.
Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer.
J Clin Invest.
2001;
107
135-42
Jung Joon Lee
Anticancer Research Laboratory
Korea Research Institute of Bioscience and Biotechnology
P.O. Box 115
Yuseong
Daejeon 305-600
Korea
Telefon: +82-42-860-4360
Fax: +82-42-860-4595
eMail: jjlee@kribb.re.kr